Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study
Multicenter cohort study compares survival outcomes in patients with esophageal cancer receiving different treatments, highlighting important implications.
Key Points
This study aims to compare survival outcomes and safety in patients receiving chemoradiotherapy with or without an immune checkpoint inhibitor.
Conducted as a multicenter cohort study.
Enrolled 290 patients treated from January 2010 to April 2024.
Stratified patients into two groups: CCRT and CCRT+ICI.
Assessed survival outcomes and safety measures.
CCRT followed by ICI maintenance improved disease-free survival (HR = 2.33, P = 0.040).
Overall survival did not improve with CCRT+ICI (HR = 1.12, P = 0.804).
Higher incidence of grade ≥ 3 leukopenia and neutropenia was noted in the CCRT+ICI group.
Lymphocyte counts decreased in both treatment groups; monocyte counts increased in the CCRT+ICI group.